Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

3. Alzheimer's Disease Treatments: With the recent approval of donanemab, Eli Lilly is well-positioned in the Alzheimer's disease space, a market with significant unmet needs and growth potential.

3. Alzheimer's Disease Treatments: With the recent approval of donanemab, Eli Lilly is well-positioned in the Alzheimer's disease space, a market with significant unmet needs and growth potential. 4.